- ≥99% by HPLC; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
Ecnoglutide
Long-acting cAMP-biased GLP-1 receptor agonist analogue (XW003), research grade
- FormLyophilized powder in a sealed glass vial with flip-off cap
- Research areasBiased GLP-1R agonism, receptor internalisation and desensitisation, glucose handling and appetite models
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Ecnoglutide, known in the development literature as XW003, is a long-acting glucagon-like peptide-1 receptor agonist analogue. Like other members of the class it is built on the GLP-1 backbone with substitutions that resist dipeptidyl peptidase-4 cleavage and a lipid side chain that promotes albumin association, together giving a much longer circulating profile than native GLP-1. What distinguishes it in published descriptions is the signalling profile: ecnoglutide has been characterised as cAMP-biased, meaning it favours Gs-coupled cAMP generation over beta-arrestin recruitment at the receptor.
We supply ecnoglutide as a lyophilized powder in 5 mg and 10 mg sealed vials, purified to ≥99% by HPLC and released with a lot-matched certificate of analysis. It ships from a United States facility and is intended exclusively for laboratory research.
Specifications
Supply & purity
- Form
- Lyophilized powder in a sealed glass vial with flip-off cap
- Purity
- ≥99% by HPLC; lot-matched COA available
- Available sizes
- 5 mg, 10 mg
- Solubility
- Bacteriostatic water; also soluble in dilute alkaline or phosphate buffers
Handling & storage
- Storage (lyophilized)
- −20 °C, sealed and protected from light and moisture
- Storage (reconstituted)
- 2–8 °C, protected from light; use within the study window
Additional detail
- Research code
- XW003
- Compound class
- Acylated long-acting GLP-1 receptor agonist analogue (incretin mimetic)
- Receptor target
- Glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR
- Signalling profile
- Reported as cAMP-biased, with reduced beta-arrestin recruitment relative to balanced agonists
- Design features
- DPP-4-resistant backbone modification plus a fatty-acid side chain for albumin association
- Research areas
- Biased GLP-1R agonism, receptor internalisation and desensitisation, glucose handling and appetite models
- Regulatory status
- Investigational; not approved by the FDA for any indication
Questions about Ecnoglutide
What is ecnoglutide?
Ecnoglutide, research code XW003, is a long-acting GLP-1 receptor agonist analogue. It carries the backbone modifications and fatty-acid acylation typical of the class, and published characterisations describe it as biased toward cAMP signalling at the receptor.
How does it differ from semaglutide?
Both are acylated mono-agonists at GLP-1R, but ecnoglutide has been reported to favour Gs/cAMP signalling with less beta-arrestin recruitment. Researchers use that difference to separate signalling-bias effects from receptor-coverage effects in comparative assays.
What purity and documentation are provided?
Each lot is purified to ≥99% by HPLC and released with a lot-matched certificate of analysis covering purity and identity. Provide the lot number printed on your vial and the COA will be supplied.
How should reconstituted ecnoglutide be stored?
Keep it at 2–8 °C, protected from light, and use it within the window your protocol specifies. Aliquoting before freezing at −20 °C avoids the freeze–thaw cycles that degrade acylated peptides fastest.
Can I buy ecnoglutide online for personal use?
No. This is a research chemical sold for laboratory use only. It is not a drug, supplement or food product and must not be administered to humans or animals.
Related
